Vaxneuvance™ (pneumococcal 15-valent conjugate) – New vaccine approval
July 16, 2021 - Merck announced the FDA approval of Vaxneuvance (pneumococcal 15-valent conjugate) vaccine for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.
Top